Skip to main content
Book ChapterOPEN ACCESS

Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Springer International Publishing, (2022), 141-145
DOI: 10.1007/978-3-030-94353-0_27
9Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A common and challenging side effect associated with CAR-T cell therapy is immune cell-associated neurotoxicity syndrome (ICANS), which occurs in 20-60% of patients, of whom 12-30% have severe (≥grade 3) symptoms.

Cite

CITATION STYLE

APA

Rees, J. H. (2022). Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In The EBMT/EHA CAR-T Cell Handbook (pp. 141–145). Springer International Publishing. https://doi.org/10.1007/978-3-030-94353-0_27

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free